WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.
The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts | ||
At W2O Group: | At LifeSci Advisors: | |
Julie Normart | Brian Ritchie | |
(559) 974-3245 | (212) 915-2578 | |
jnormart@w2ogroup.com | britchie@lifesciadvisors.com |
Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…
Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…
Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…
Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Findable research is fundable research BOSTON, June 11, 2024 /PRNewswire/ -- OpenScholar announced immediate availability of…